Clinical Trial

Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After CABG

Study acronym: L-RIPC-CABG

Recruiting

Record status

This record was last updated September 18, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Summary

Remote Ischemic preconditioning (RIPC) has been reported to improve myocardial microcirculation, promote collateral circulation recruitment, and improve myocardial perfusion in patients.Two large randomized controlled trials demonstrated a perioperative cardioprotective effect of RIPC (reduced troponin levels), but did not find that a single preoperative RIPC improved long-term outcomes of coronary artery bypass grafting(CABG).The effect of a single RIPC before CABG may be too short. This study aims to investigate whether long-term RIPC improved myocardial perfusion in patients 3 months and 6 months after CABG surgery , and to detect changes in blood vascular endothelial growth factor, Nitrc Oxide, adenosine，and Endothelin-1, and to observe MACCE event rates at 12 months.

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2021-02-28; most recent amendment 2025-09-12.

Status change: Not Yet Recruiting → Recruiting 2021-04-27

Trial Details

NCT Number	NCT04779008
Lead Sponsor	Henan Institute of Cardiovascular Epidemiology
Conditions	Coronary Disease
Enrollment	210 participants
Start Date	2021-03-10
Primary Completion	2025-12-01 (estimated)
Study Completion	2026-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-09-18